Home

 

Recent News


DOLF Team Attends NTD Summit, Present IDA Results

Donors, endemic countries, researchers and program managers came together at the NTD Summit in Geneva, Switzerland between April 19-22 to celebrate progress and set a path towards meeting the 2020 goals for eliminating neglected tropical diseases.  Five members of the DOLF team attended the NTD Summit to share important results with the NTD community. The meeting was also an opportunity for DOLF researchers to canvas attendees about how the DOLF might serve as a platform to address key challenges faced by NTD elimination programs for 2020 and beyond.

There was a lot of interest at the meeting in triple drug treatment for lymphatic filariasis. DOLF Project clinical trials led by Dr. Chris King have shown a triple-drug combination (ivermectin plus DEC with albendazole, or IDA) is superior to standard two-drug combinations for treatment of lymphatic filariasis. IDA could be a game changer for the LF elimination program by reducing the time it takes to reach elimination targets.  However, safety studies are needed before IDA can be recommended for use by national filariasis elimination programs.  DOLF principal investigator Dr. Gary Weil presented at talk on IDA at the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) meeting in Geneva. He shared encouraging results from a multicenter safety study with more than 23,000 participants that was recently conducted by DOLF partners in 4 countries.  The World Health Organization will convene an expert committee to consider the potential value of IDA for the Global Programme to Eliminate Lymphatic Filariasis later this year.


Triple-drug Safety Study Reaches Important Milestone

The DOLF project celebrated an important milestone on February 9th. Our Community Based Safety Study of 2-drug vs. 3-drug Therapy for Lymphatic Filariasis completed enrolling and treating 10,000 participants in each of the treatment arms. This achieves the primary objective of the study: measuring the treatment related adverse events following treatment with the 3-drug combination therapy as compared to the standard 2-drug therapy. Soon, DOLF investigators will provide the dataset to an independent review committee at the WHO. This is the first step toward a WHO decision about whether to recommend the 3-drug therapy for mass drug administration programs to eliminate lymphatic filariasis outside of Africa.

Many people across the globe have worked hard to reach this milestone. In September 2015 the study was proposed at a meeting in Seattle. Seventeen months later DOLF collaborators have dosed more than 20,000 participants across 4 countries! But, the work is not over. While enrollment is completed at study sites in Indonesia and Haiti, our collaborators in India and Papua New Guinea will continue until they have reached their enrollment targets. A related study will soon be initiated at a fifth site in Fiji. Other aspects of the study including community acceptance surveys, and efficacy follow-up studies will continue into 2018.

HaitiDistribution IndonesiaEnrollment
Study staff enrolling and distributing drugs at sites in Haiti and Indonesia. Teams like these have worked hard to enroll more than 20,000 participants in 5 months across study sites in Haiti, India, Indonesia, and Papua New Guinea.


DOLF Shows off Innovative Electronic Data Capture Tool for Clinical Trials at COR-NTD Meeting - November 10, 2016

Joshua Bogus, Project Manager for the DOLF project, supported by the Gates Foundation, presenting the CliniOps eSource solution, at the Coalition for Operational Research on Neglected Tropical Disease Conference (COR-NTD), Atlanta, Nov, 2016

Joshua Bogus, Project Manager for the DOLF project, supported by the Gates Foundation, presenting the CliniOps eSource solution, at the Coalition for Operational Research on Neglected Tropical Disease Conference (COR-NTD), Atlanta, Nov, 2016

Last November at the COR-NTD Innovation Lab in Atlanta DOLF Project Manager, Joshua Bogus, demonstrated the capabilities of a tablet-based electronic data capture system that is being used in the Community Based Safety Study of 2-drug vs. 3-drug Therapy for Lymphatic Filariasis. This study is set to collect about 30,000 patient data, across 5 countries, within a span of 12 months.

The DOLF project team implemented CliniTrial, a proprietary mobile, cloud-based data collection solution for clinical trials developed by CliniOps (http://cliniops.com). The system allows data to be collected off-line and uploaded later. This overcame a major obstacle faced by the DOLF team in attempting to collect data electronically without regular internet access at some of the remote study sites. Joshua Bogus presented CliniTrial to other neglected tropical disease researchers and explained how they might use the system in their own clinical trials.

 


© 2010 D O L F (Death to Oncho and LF) Last updated on 21 December 2010 Suffusion WordPress theme by Sayontan Sinha